| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
Uridine (formerly NSC 20256; NSC-20256; NSC20256) is a glycosylated pyrimidine-analog containing uracil attached to a ribose ring, specifically, a ribofuranose, via a β-N1-glycosidic bond. It is one of the five essential nucleosides—the others being adenosine, thymidine, cytidine, and guanosine—that make up nucleic acids, or DNA/RNA. Common abbreviations for the five nucleosides are U, A, T, C, and G, in that order.
| Targets |
Human Endogenous Metabolite
|
|---|---|
| Toxicity/Toxicokinetics |
Toxicity Data
Mouse(ip): LD50 4335 mg/kg |
| References |
Wikipedia
|
| Additional Infomation |
Uridine is a ribonucleoside composed of a molecule of uracil attached to a ribofuranose moiety via a beta-N(1)-glycosidic bond. It has a role as a human metabolite, a fundamental metabolite and a drug metabolite. It is functionally related to a uracil.
RG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential for cell metabolism. Uridine is synthesized by the mitochondria, the power plant of the human cell responsible for energy metabolism. The rationale for uridine therapy in neuropsychiatric disorders is supported by preclinical and clinical research. Recent reports indicate that certain genes that encode for mitochondrial proteins are significantly down regulated in the brains of bipolar patients. This new insight suggests that the symptoms of bipolar disorder may be linked to dysregulation of energy metabolism of the brain. Uridine is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Uridine is a Pyrimidine Analog. The chemical classification of uridine is Pyrimidines, and Analogs/Derivatives. Uridine has been reported in Nigrospora oryzae, Rehmannia glutinosa, and other organisms with data available. Uridine is a nucleoside consisting of uracil and D-ribose and a component of RNA. Uridine has been studied as a rescue agent to reduce the toxicities associated with 5-fluorouracil (5-FU), thereby allowing the administration of higher doses of 5-FU in chemotherapy regimens. (NCI04) Uridine is a metabolite found in or produced by Saccharomyces cerevisiae. A ribonucleoside in which RIBOSE is linked to URACIL. Drug Indication Investigated for use/treatment in bipolar disorders and manic disorders. |
| Molecular Formula |
C9H12N2O6
|
|
|---|---|---|
| Molecular Weight |
244.2
|
|
| Exact Mass |
244.069
|
|
| Elemental Analysis |
C, 44.27; H, 4.95; N, 11.47; O, 39.31
|
|
| CAS # |
58-96-8
|
|
| Related CAS # |
|
|
| PubChem CID |
6029
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.9±0.1 g/cm3
|
|
| Boiling Point |
567.9±60.0 °C at 760 mmHg
|
|
| Melting Point |
163-167 °C(lit.)
|
|
| Flash Point |
297.2±32.9 °C
|
|
| Vapour Pressure |
0.0±3.5 mmHg at 25°C
|
|
| Index of Refraction |
1.732
|
|
| LogP |
-1.55
|
|
| Hydrogen Bond Donor Count |
4
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
17
|
|
| Complexity |
371
|
|
| Defined Atom Stereocenter Count |
4
|
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@]([H])([C@]1([H])N1C([H])=C([H])C(N([H])C1=O)=O)O[H])O[H]
|
|
| InChi Key |
DRTQHJPVMGBUCF-XVFCMESISA-N
|
|
| InChi Code |
InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8-/m1/s1
|
|
| Chemical Name |
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.03.00
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (10.24 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 40 mg/mL (163.80 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0950 mL | 20.4750 mL | 40.9500 mL | |
| 5 mM | 0.8190 mL | 4.0950 mL | 8.1900 mL | |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.0950 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03265964 | Recruiting | Drug: Uridine Drug: Placebo |
Suicidal Ideation | VA Office of Research and Development |
April 2, 2018 | Phase 4 |
| NCT01261260 | Completed | Drug: Uridine | Healthy Male Subjects | Mclean Hospital | November 2006 | Phase 1 |
| NCT02110147 | Completed | Drug: uridine triacetate | Hereditary Orotic Aciduria | Wellstat Therapeutics | April 2014 | Phase 3 |
| NCT00841269 | Completed | Drug: Uridine | Bipolar Disorder | University of Utah | May 2009 | Phase 2 |
| NCT01805440 | Completed | Drug: Uridine Drug: Placebo |
Bipolar Disorder Bipolar Depression |
University of Utah | August 2013 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA